Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Argonaute2 promotes myeloma angiogenesis by deregulation of microRNAs

View through CrossRef
Abstract Dysregulation of miRNAs expression contributes to cancer cell proliferation, apoptosis and angiogenesis. Angiogenesis is a hallmark of multiple myeloma development and progression. Argonaute 2 (AGO2) protein, the core component of RNA-induced silencing complex (RISC), can directly bind miRNAs and mediate target mRNAs degradation. Previous study showed that AGO2 knockdown suppressed the growth and tube formation of HUVECs. In current study, the supernatant of AGO2 over-expression MM lines could induce HUVECs migration and accelerated tube formation. Conversely, the supernatant of AGO2 knockdown MM lines could suppress cell migration and tube formation of HUVECs. Moreover, CAM assay also demonstrated AGO2 can drive neovessel formation of MM in vivo. Using miRNAs microarray, we observed that 25 miRNAs were up-regulated and 14 miRNAs were down-regulated by AGO2 protein. Among these AGO2-associated miRNAs, most Let-7 family and two miR-17-92 cluster members (miR-17a and miR-92-1), known as pro-angiogenetic miRNAs, were the dominant positively regulated miRNAs by AGO2, and the anti-angiogenetic miRNAs, such as miR-145 and miR-361 were inversely regulated by AGO2 protein, which play crucial role in AGO2 mediating angiogenesis. Disclosures: No relevant conflicts of interest to declare.
Title: Argonaute2 promotes myeloma angiogenesis by deregulation of microRNAs
Description:
Abstract Dysregulation of miRNAs expression contributes to cancer cell proliferation, apoptosis and angiogenesis.
Angiogenesis is a hallmark of multiple myeloma development and progression.
Argonaute 2 (AGO2) protein, the core component of RNA-induced silencing complex (RISC), can directly bind miRNAs and mediate target mRNAs degradation.
Previous study showed that AGO2 knockdown suppressed the growth and tube formation of HUVECs.
In current study, the supernatant of AGO2 over-expression MM lines could induce HUVECs migration and accelerated tube formation.
Conversely, the supernatant of AGO2 knockdown MM lines could suppress cell migration and tube formation of HUVECs.
Moreover, CAM assay also demonstrated AGO2 can drive neovessel formation of MM in vivo.
Using miRNAs microarray, we observed that 25 miRNAs were up-regulated and 14 miRNAs were down-regulated by AGO2 protein.
Among these AGO2-associated miRNAs, most Let-7 family and two miR-17-92 cluster members (miR-17a and miR-92-1), known as pro-angiogenetic miRNAs, were the dominant positively regulated miRNAs by AGO2, and the anti-angiogenetic miRNAs, such as miR-145 and miR-361 were inversely regulated by AGO2 protein, which play crucial role in AGO2 mediating angiogenesis.
Disclosures: No relevant conflicts of interest to declare.

Related Results

Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
<div>Abstract<p><b>Purpose:</b> B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this stud...
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
<div>Abstract<p><b>Purpose:</b> B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this stud...
MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma
MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma
Abstract Multiple myeloma (MM) is a malignancy of terminally differentiated clonal plasma cells displaying significant molecular heterogeneity with 7 subgroups defin...
Plasma Cell Disorders
Plasma Cell Disorders
Multiple myeloma represents 1.4% of all new patients with cancer and will result in an estimated 11,090 deaths in 2014. It is twice as common in black men as in white men and 2.5 t...
Plasma Cell Disorders
Plasma Cell Disorders
Multiple myeloma represents 1.4% of all new patients with cancer and will result in an estimated 11,090 deaths in 2014. It is twice as common in black men as in white men and 2.5 t...
Focal MIBI uptake is a better indicator of active myeloma than diffuse uptake
Focal MIBI uptake is a better indicator of active myeloma than diffuse uptake
Abstract:  Purpose: Technetium‐99m 2‐methoxyisobutylisonitrile (MIBI) imaging has been proposed as a front‐line investigation to detect bone disease both before and after the trea...
Abstract 1708: Heparanase regulates response to chemotherapy in myeloma
Abstract 1708: Heparanase regulates response to chemotherapy in myeloma
Abstract Following therapy, essentially all multiple myeloma patients relapse due to a population of chemoresistant cells leading to eventual patient death. Our lab ...
Pathogenesis of bone disease in multiple myeloma: from bench to bedside
Pathogenesis of bone disease in multiple myeloma: from bench to bedside
AbstractOsteolytic bone disease is the hallmark of multiple myeloma, which deteriorates the quality of life of myeloma patients, and it affects dramatically their morbidity and mor...

Back to Top